Streetbeat News

Products Services

MSFT

SONY

Epic Games has launched the 'Now on Epic' program to encourage developers to bring their older games to the Epic Games Store. The program offers a 100% revenue share for the first six months of release, after which it reverts to an 88%/12% split. To qualify, developers must commit to releasing at least three games before October 31, 2023, on other platforms such as Microsoft's Xbox Game Pass or Sony's PlayStation Plus. The move is part of Epic Games' strategy to compete more effectively in the digital gaming marketplace.

Portfolio Pulse from Franca Quarneti

October 17, 2023 | 9:06 pm

MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced that the FDA has extended the review of the sNDA for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with PFIC. The new PDUFA date is March 13, 2024. The FDA extended the date to allow time for a full review of a submission provided in response to an FDA information request. No additional data or studies have been requested.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:37 pm

AMZN

MSFT

Microsoft is reportedly preparing to bring Amazon on board as a customer of its 365 cloud tools in a deal worth $1 billion. Amazon is expected to start setting up the new systems in early November.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:33 pm

ORIC

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. A conference call and webcast will be hosted by ORIC on October 21, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:31 pm

MRTX

Mirati Therapeutics has presented late-breaking results evaluating the combination of Adagrasib and Pembrolizumab in first-line non-small cell lung cancer (NSCLC). The data shows a manageable safety profile and early signs of durability of Adagrasib in combination with a checkpoint inhibitor in the first-line NSCLC setting.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:25 pm

BLTE

Belite Bio has announced its submission to the National Medical Products Administration (NMPA) for the Phase 3 clinical trial of Tinlarebant in China. The drug is aimed at treating gouty arthritis (GA).

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:24 pm

BIDU

MSFT

Baidu (NASDAQ:BIDU) has launched an upgraded version of its AI chatbot, Ernie Bot 4.0, which is said to outperform Microsoft (NASDAQ:MSFT)-backed ChatGPT in some Chinese-language tasks. The bot, which is not yet accessible to the public, can understand complex questions, generate pictures, and handle basic arithmetic. Baidu plans to integrate Ernie Bot into search, maps, file-sharing, work collaboration, and data analytics. The company also sees Ernie Bot as a core business that will help regain users lost to apps run by ByteDance Ltd. and Tencent.

Portfolio Pulse from Khyathi Dalal

October 17, 2023 | 8:20 pm

VMI

Valmont Industries, Inc. (VMI) has entered into a strategic partnership with FieldSync, a digital transformation solutions provider. The partnership aims to develop product solutions that drive digital transformation.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:18 pm

SP

SP Plus Corporation has launched its AeroParker online booking reservation system at airports in Illinois, Kentucky, South Dakota, and Texas. This move is expected to enhance the company's service offerings and potentially increase its revenue.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:11 pm

VKTX

Viking Therapeutics (NASDAQ:VKTX) has presented new data from its Phase 1 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist, at ObesityWeek 2023. The data shows that 28 days of treatment with VK2735 resulted in significant reductions in liver fat content and plasma lipid levels. The treatment also resulted in weight loss of up to 7.8% from baseline. The company believes these results suggest potential benefits for patients with obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:08 pm